Aqilion’s CEO: “We are driven by dealmaking and scientific data”
With four independent programmes in its pipeline, the Swedish biotech Aqilion is positioned for a series of significant upcoming milestones. CEO Sarah Fredriksson joined BioStock’s studio to share updates on the progress of these programmes, key takeaways from the pre-IND meeting with the FDA, and the lasting impact of Aqilion’s previous major deal with Merck — both within the organisation and in its drive to forge new collaborations.
Watch the interview with CEO Sarah Fredriksson below:
